naltrexone / Generic mfg. - LARVOL DELTA

Correlations between wastewater levels of naloxone and substance use disorder treatment medications with treatment encounters and overdoses - Marin County, California, USA, March 2023-June 2024. (PubMed, Public Health) - "Wastewater surveillance for MOUDs and naloxone might aid in assessing treatment gaps and tracking progress towards overdose harm reduction and substance use disorder treatment goals. Correlations between increases in community-level buprenorphine levels and reduced overdoses highlight the importance of bolstering access to treatment."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Substance Abuse

Olanzapine/Samidorphan (Lybalvi) and Buprenorphine: Considerations for a Contradictory Combination: A Case Report. (PubMed, J Addict Med) - "This case report outlines the safety concerns of utilizing an opioid antagonist (samidorphan) in conjunction with an opioid partial agonist (buprenorphine) and demonstrates the process for safe transition to an alternative regimen."

Journal • Addiction (Opioid and Alcohol) • Bipolar Disorder • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder • Psychiatry • Schizophrenia • Substance Abuse

Low-Dose Oral Naltrexone for Darier Disease. (PubMed, Cutis) - No abstract available

Journal

Analyzing the Discursive Framing of Medications for Opioid Use Disorder (MOUDs) in U.S. News Media: A Comparative Study of Benefits, Persuasion Methods, and Temporal Trends. (PubMed, Health Commun) - "Buprenorphine benefits were most frequently detailed (n = 35), followed by methadone (n = 24) and naltrexone (n = 13). Communication about MOUDs in the media warrants improvement, with implications for public and policymaker understanding and support. Future research should focus on identifying effective media strategies to enhance public awareness and acceptance of MOUD benefits."

Journal • Addiction (Opioid and Alcohol) • Human Immunodeficiency Virus • Infectious Disease • Substance Abuse

Comparison of Naltrexone Implant and Oral Buprenorphine Naloxone in The Treatment of Opioid Use Disorder: A Retrospective Cohort Study. (PubMed, Noro Psikiyatr Ars) - "The findings of our study show that XR-NTX may be more effective than BN-NX in preventing relapse in OUD. In addition, it was concluded that probation, age of onset of substance use, multiple substance use, number of inpatient treatments and longest period of abstinence were predictive factors in terms of relapse."

Journal • Retrospective data • Addiction (Opioid and Alcohol) • Substance Abuse

NALTREXONE-ASSOCIATED EOSINOPHILIC PNEUMONIA: WHEN THE CURE BECOMES A PULMONARY CHALLENGE (CHEST 2025) - No abstract available

Infectious Disease • Pneumonia • Respiratory Diseases

Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder by Race and Ethnicity and Insurance Type. (PubMed, JAMA Netw Open) - "In this cohort study of more than 17 600 opioid-related index health care events, race and ethnicity-based and insurance-based disparities in access to MOUD persisted despite efforts to expand treatment availability. These findings underscore the need for targeted interventions, including culturally tailored care, expanded access points, and policy reforms to address structural barriers and reduce inequities contributing to the overdose crisis."

Journal • Reimbursement • Retrospective data • US reimbursement • Addiction (Opioid and Alcohol) • Infectious Disease • Substance Abuse

Docking Simulations of G-Protein Coupled Receptors Uncover Crossover Binding Patterns of Diverse Ligands to Angiotensin, Alpha-Adrenergic and Opioid Receptors: Implications for Cardiovascular Disease and Addiction. (PubMed, Biomolecules) - "ARBs that exhibit higher affinities for AT1R also demonstrate higher affinities for µORs and ժORs than opiate ligands, such as fentanyl and naltrexone. Moreover, ARBs had a higher affinity for αARs than either alpha agonists (epinephrine and phenylephrine) or inhibitors (prazosin and doxazosin)...ARBs have the potential to inhibit morphine tolerance and appear to disrupt receptor desensitization processes, potentially by competing at the D-site. Our results suggest the possible therapeutic potential of ARBs in treating methamphetamine and opiate addictions."

Journal • Addiction (Opioid and Alcohol) • Cardiovascular • CNS Disorders • Psychiatry

Combination of Drugs in the Treatment of Alcohol Use Disorder: A Meta-Analysis and Meta-Regression Study. (PubMed, Brain Sci) - " Combined pharmacotherapies are more effective than monotherapy in enhancing abstinence rates in AUD treatment, with naltrexone, acamprosate, and sertraline emerging as key adjunctive agents promoting these outcomes. These findings underscore the complexity of AUD as a multifactorial psychiatric condition and highlight the potential of combined pharmacotherapy as a promising strategy for achieving better treatment outcomes, particularly in terms of abstinence rates."

Clinical • Journal • Retrospective data • Review • Addiction (Opioid and Alcohol) • Psychiatry

Predicting individual treatment response in alcohol use disorders: a reverse translational proof-of-concept study. (PubMed, Transl Psychiatry) - "We hypothesized that a preclinical model of AUD accounting for inter-individual heterogeneity would predict the lack of efficacy of a drug that failed clinical trials (Memantine) and the efficacy of an approved AUD medication (Naltrexone). These results advocate the use of inter-individual heterogeneity for preclinical prediction of drug efficacy in AUD before clinical trials. In addition, we observed sex differences in response to Naltrexone that can be back-translated in clinic."

Journal • Addiction (Opioid and Alcohol)

Involvement of enkephalinergic system in the reproductive stress response of the gecko Hemidactylus frenatus. (PubMed, Psychoneuroendocrinology) - "Nonetheless, the functional importance of the two forms of enkephalins, methionine-enkephalin (M-ENK) and leucine-enkephalin (L-ENK), remains inadequately understood in the context of the reproductive stress response in reptiles...In the second experiment, the administration of mu or delta opioid receptor antagonists, naltrexone or naltrindole, respectively, reinstated the stress-induced reduction of gonadotropin-releasing hormone immunoreactivity in the hypothalamus, ME, and PD. These treatments also restored the presence of stage IV and V (vitellogenic) follicles, which were absent in the stress-only group. The findings for the first time indicate the activation of enkephalinergic system in the hypothalamus, ME, and PD during the stress response and suggest that the stress-induced suppression of the seasonal ovarian recrudescence phase is attenuated through the administration of mu or delta opioid receptor antagonists in reptiles."

Journal • PENK

Treatment of Hailey-Hailey disease with the Janus kinase inhibitor abrocitinib: A case report. (PubMed, SAGE Open Med Case Rep) - "Despite multiple failed therapies, including methotrexate, dapsone, acitretin, and naltrexone, she showed rapid improvement within 2 weeks of abrocitinib (100 mg daily), a JAK1 inhibitor, with sustained control at 2 months follow-up. This case adds to growing evidence that JAK inhibitors, particularly abrocitinib, may serve as an effective targeted therapy for refractory Hailey-Hailey disease. Further clinical trials are needed to confirm its long-term efficacy and safety."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Genetic Disorders • Immunology • Inflammation • Pain • IL13 • IL4

Conducting an implementation intervention study with American Indian and Alaska native communities: Methodological considerations. (PubMed, Contemp Clin Trials) - P=N/A | "This is the first study to develop and evaluate an implementation intervention to culturally center MOUD delivery in AI/AN communities. Implementation science and CBPR are complimentary for co-developing strategies with AI/AN communities to integrate Indigenous and Western best practices, which may ultimately reduce opioid-related mortality among AI/AN peoples and enhance Indigenous community wellness. Clinical Trials NCT Registration Number:NCT04958798."

Journal • Addiction (Opioid and Alcohol) • Mood Disorders • Substance Abuse

Methadone-fluconazole formulations provide superior clinical efficacy compared to buprenorphine injection in dogs undergoing soft tissue surgery. (PubMed, Am J Vet Res) - "To determine the perioperative efficacy and safety of methadone-fluconazole injection followed by oral methadone-fluconazole-naltrexone (methadone-fluconazole) compared to IM buprenorphine followed by oral codeine (buprenorphine)...Preoperative sedation included acepromazine; anesthetic induction included ketamine-midazolam and isoflurane anesthesia...Methadone-fluconazole formulations provided superior clinical efficacy compared to buprenorphine. Methadone-fluconazole formulations provide effective analgesia with twice-daily administration."

Journal • Anesthesia • Gynecology • Hypotension • Pain

Explaining increased efficacy of naltrexone in the treatment of alcohol dependent patients with a family history of alcohol use disorder: A systematic review on the role of reward sensitivity and sweet liking. (PubMed, Alcohol) - "Increased reward sensitivity (and sweet-liking as its possible indicator) appeared to be positively associated with FHA+ and was attenuated by NTX, which may (partly) explain the increased effect of NTX in FHA+ AUD patients. These results may foster personalized pharmacotherapy in AUD patients."

Journal • Review • Addiction (Opioid and Alcohol)

A Meta-Analysis on the Effect of Depression on Adherence to Medication for Opioid Use Disorder. (PubMed, J Dual Diagn) - "The literature was limited by few studies examining naltrexone, limited diversity of samples, and a lack of clear consensus on adherence measurement. Future research should test whether this relationship extends to naltrexone; use samples with more racial minorities, women and gender minorities, and inpatient samples; clearly define and measure adherence, and identify mechanisms and moderators of this relationship, to best inform future clinical applications and improve outcomes for those with OUD."

Journal • Retrospective data • Review • Addiction (Opioid and Alcohol) • CNS Disorders • Depression • Mood Disorders • Psychiatry • Substance Abuse

Granulomatous tattoo reaction associated with poly (lactic-co-glycolic acid) (PLGA) microsphere-based naltrexone injections. (PubMed, JAAD Case Rep) - No abstract available

Journal

Treatment Algorithm Suggestion for Hailey-Hailey Disease. (PubMed, J Cutan Med Surg) - "Treatments include topical agents (corticosteroids, calcineurin inhibitors, antibiotics, calcitriol) and systemic agents (antibiotics, anticholinergics, retinoids, apremilast, dapsone, immunosuppressants, biologicals, naltrexone, vitamin D), as well as procedural therapy such as carbon dioxide laser, botulinum toxin, dermabrasion, photodynamic therapy, and surgery. This review presents a systematic analysis of the literature with a focus on both established and emerging treatment options for Hailey-Hailey disease with the aim to provide a therapeutic algorithm. The evidence supporting each treatment option will be assessed, emphasizing the strength of the data to guide clinical decision-making."

Journal • Review • Dermatology • Genetic Disorders

Overview of authorised drugs to be repurposed for the treatment of osteoarthritis: a scoping review of clinical studies (EULAR 2025) - "Drugs examined less than 5 times, including spironolactone, doxycycline, liraglutide, thiazolidinediones, anti-histamines, ticagrelor, β-blockers, coumarins, anti-IL1, anti-IL6, sodium bicarbonate and calcium gluconate, fenofibrate, somatropin, pentosan polysulfate, insulin, N-acetylcysteine, naltrexone, bromelain, fish oil, L-carnitine, folate, vitamin C, and vitamin K showed similar results (data not shown). Many authorised drugs have already been investigated to be repurposed for the treatment of OA, of which the most extensively investigated mainly targeted the inflammatory and bone endotype. Short-term studies investigated almost exclusively symptom-modifying effects, whereas most long-term studies investigated structure-modifying effects as well. However, long-term studies investigating structural-modifying effects of colchicine, methotrexate, and hydroxychloroquine are lacking."

Clinical • Review • Immunology • Oncology • Orthopedics • Osteoarthritis • Pain • Rheumatology

Effects of orally self-administered furanyl fentanyl and acryl fentanyl in mice: antinociception, dependence and withdrawal, and defense of consumption. (PubMed, Neuropharmacology) - "Brief access to supplemental water, injection of the μ-opioid antagonist naltrexone, or administration of the μ-opioid agonist morphine all attenuated the defense of FA consumption. Consumption of acryl fentanyl also abolished weight gain across the study, and disrupted nest-building. The results of these experiments suggest that mice drinking furanyl fentanyl or acryl fentanyl experience opioid-mediated effects including antinociception, dependence and withdrawal, and abuse-related subjective effects, and provide proof of concept for use of this model to assess pharmacological and non-pharmacological manipulations which may attenuate the reinforcing effects of oral fentanyl and FAs."

Journal • Preclinical • Addiction (Opioid and Alcohol) • Substance Abuse

Reducing Residual Solvent Levels in Poly (D, L-lactic-co-glycolic acid) Microspheres: A Roadmap for Scalable Industrial Production. (PubMed, Drug Dev Ind Pharm) - "These modifications greatly affected the residual solvent amount as well as other physicochemical properties of microspheres including size, morphology, and release profile. Overall, some practical methods could be used for feasible industrial production of PLGA microspheres."

Journal

Substance Use Treatment Services in New York (2021-2023): A State Profile Analysis Based on National Survey of Substance Abuse and Mental Health Services (N-SUMHSS) Data. (PubMed, Cureus) - "MAT utilization has improved, but challenges persist in addressing the growing demand for residential and detox services. Expanding outpatient and inpatient services, along with greater access to MAT, is crucial to improving treatment in New York."

Journal • Substance Abuse

The contributions of taste cues to ethanol responses in female and male rats. (PubMed, Physiol Behav) - "In experiment 2, unconditioned lick responses to an array of ethanol concentrations (1-32%) were measured in rats following administration (i.p.) of saline, 0.1 or 1.0 mg/kg naltrexone, an opioid receptor antagonist...Opioidergic signaling that drives the appetitive components of behavior towards ethanol is similar for females and males but differs for some components of consummatory behavior. Thus, sex differences in responses to ethanol do not appear to be primarily driven by variability in qualitative components of ethanol that contributes to consummatory aspects of ingestive behavior, but more likely by reward-related signaling."

Journal • Preclinical

A Randomized, Double-Blind, Single-Center Clinical Study on the Efficacy of Naltrexone Implant in Antagonizing Opioid Agonist Hydromorphone (clinicaltrials.gov) - P2 | N=31 | Completed | Sponsor: Shenzhen Sciencare Medical Industries Co., Ltd.

New P2 trial • Addiction (Opioid and Alcohol)

OPRM1 A118G Polymorphisms and Naltrexone Treatment Response among Taiwanese Patients with Alcohol Use Disorder (CINP-AsCNP 2025) - "Naltrexone treatment significantly reduced drinking and psychological symptoms in Taiwanese AUD patients, with G allele carriers showing more pronounced improvements in craving compared to A/A genotype carriers. Naltrexone treatment reduced depressive symptoms faster in G allele carriers compared to A/A genotype carriers. The study suggests the potential for precision treatment with naltrexone based on OPRM1 A118G polymorphisms in patients with AUD in Asian."

Clinical • Addiction (Opioid and Alcohol) • CNS Disorders • Mood Disorders • Psychiatry • OPRM1